A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170)

Edward Maldonado, W. Kimryn Rathmell, Geoffrey I. Shapiro, Naoko Takebe, Jordi Rodon, Devalingam Mahalingam, Nikolaos A. Trikalinos, Arash R. Kalebasty, Mamta Parikh, Scott A. Boerner, Celene Balido, Gregor Krings, Timothy F. Burns, Emily K. Bergsland, Pamela N. Munster, Alan Ashworth, Patricia LoRusso, Rahul R. Aggarwal

Open source

DOI: 10.1158/2767-9764.crc-24-0213
Published: 2024-07-01
Container: Cancer Research Communications
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2767-9764.crc-24-0213,
  title = {A Phase II Trial of the WEE1 Inhibitor Adavosertib in
                    <i>SETD2</i>
                    <i>-</i>
                    Altered Advanced Solid Tumor Malignancies (NCI 10170)},
  author = {Edward Maldonado and W. Kimryn Rathmell and Geoffrey I. Shapiro and Naoko Takebe and Jordi Rodon and Devalingam Mahalingam and Nikolaos A. Trikalinos and Arash R. Kalebasty and Mamta Parikh and Scott A. Boerner and Celene Balido and Gregor Krings and Timothy F. Burns and Emily K. Bergsland and Pamela N. Munster and Alan Ashworth and Patricia LoRusso and Rahul R. Aggarwal},
  year = {2024},
  journal = {Cancer Research Communications},
  doi = {10.1158/2767-9764.crc-24-0213},
  url = {https://doi.org/10.1158/2767-9764.crc-24-0213}
}

RIS

TY  - JOUR
TI  - A Phase II Trial of the WEE1 Inhibitor Adavosertib in
                    <i>SETD2</i>
                    <i>-</i>
                    Altered Advanced Solid Tumor Malignancies (NCI 10170)
AU  - Edward Maldonado
AU  - W. Kimryn Rathmell
AU  - Geoffrey I. Shapiro
AU  - Naoko Takebe
AU  - Jordi Rodon
AU  - Devalingam Mahalingam
AU  - Nikolaos A. Trikalinos
AU  - Arash R. Kalebasty
AU  - Mamta Parikh
AU  - Scott A. Boerner
AU  - Celene Balido
AU  - Gregor Krings
AU  - Timothy F. Burns
AU  - Emily K. Bergsland
AU  - Pamela N. Munster
AU  - Alan Ashworth
AU  - Patricia LoRusso
AU  - Rahul R. Aggarwal
PY  - 2024
JO  - Cancer Research Communications
DO  - 10.1158/2767-9764.crc-24-0213
UR  - https://doi.org/10.1158/2767-9764.crc-24-0213
ER  -

APA

Maldonado, E., Rathmell, W. K., Shapiro, G. I., Takebe, N., Rodon, J., Mahalingam, D., Trikalinos, N. A., Kalebasty, A. R., Parikh, M., Boerner, S. A., Balido, C., Krings, G., Burns, T. F., Bergsland, E. K., Munster, P. N., Ashworth, A., LoRusso, P., & Aggarwal, R. R. (2024). A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-24-0213

Source records

crossref · retrieved 2026-09-26T12:39:03.425Z

A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records